Acta Medica Okayama 73巻 2号
2019-04 発行
Okamura, Tomoka
Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Washio, Yousuke
Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yoshimoto, Junko
Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Tani, Kazumasa
Department of Obstetrics and Gynecology, Okayama University Hospital
Tsukahara, Hirokazu
Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Shimada, Akira
Department of Pediatric Hematology/Oncology, Okayama University Hospital
Most cases of transient abnormal myelopoiesis (TAM) in neonates with Down syndrome (DS) resolve spontaneously; however, DS-TAM neonates with hydrops fetalis (HF) show poor clinical outcomes. We report three infants with DS-TAM and HF who were treated with exchange transfusion (ET) followed by low-dose cytarabine (LD-CA). All of them survived without developing liver failure, acute leukemia, or other serious adverse events. Our results suggest that this combination treatment with ET and LD-CA would be safe, tolerable and effective as an novel approach for DS-TAM patients with HF.
cytarabine
Down syndrome
exchange transfusion
hydrops fetalis
transient abnormal myelopoiesis